Association of statins with inflammatory cytokines: A population-based Colaus study

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 253-258

  Lyngdoh, Tanica ^a   Vollenweider, Peter ^b   Waeber, Gérard ^b   Marques Vidal, Pedro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CRP; Cytokines; IL 1 ; IL 6; Population study; Statins; TNF

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLEIOTROPY; POPULATION RESEARCH; PRIORITY JOURNAL; SWITZERLAND;

ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; SWITZERLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055009005     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.117     Document Type: Article

References (33)

1. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83(February (2)):456S-460S.
2. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108(November 11 (19)):2317-2322.
3. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. JAMA 1998, 279(May 27 (20)):1643-1650.
4. Marz W., Winkler K., Nauck M., Bohm B.O., Winkelmann B.R. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol 2003, 92(August 1 (3)):305-308.
5. Kwak B.R., Mulhaupt F., Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003, 2(October (6)):332-338.
6. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998, 18(November (11)):1671-1678.
7. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010, 25(July (4)):399-405.
8. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004, 177(November (1)):161-166.
9. Gurgun C., Ildizli M., Yavuzgil O., et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008, 123(January 11 (2)):102-107.
10. Ando H., Sugimoto K., Yanagihara H., et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008, 35(September (9)):1012-1017.
11. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001, 77(February (2-3)):247-253.
12. Nilsson L., Eriksson P., Cherfan P., Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation 2010.
13. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353(March 20 (9157)):983-984.
14. Yoon S.S., Dillon C.F., Carroll M., Illoh K., Ostchega Y. Effects of statins on serum inflammatory markers: the U.S. National Health and Nutrition Examination Survey 1999-2004. J Atheroscler Thromb 2010.
15. McCaffery J.M., Frasure-Smith N., Dube M.P., et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006, 68(March (2)):187-200.
16. Preisig M., Waeber G., Vollenweider P., et al. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry 2009, 9:9.
17. Firmann M., Mayor V., Vidal P.M., et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008, 8:6.
18. Vignali D.A. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000, 243(September 21 (1-2)):243-255.
19. von K.R., Begre S., Abbas C.C., Saner H., Gander M.L., Schmid J.P. Inflammatory biomarkers in patients with posttraumatic stress disorder caused by myocardial infarction and the role of depressive symptoms. Neuroimmunomodulation 2010, 17(1):39-46.
20. Fichorova R.N., Richardson-Harman N., Alfano M., et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008, 80(June 15 (12)):4741-4751.
21. Hornung R., Reed L. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 1990, 5:46-51.
22. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203(April (2)):325-330.
23. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104(July 17 (3)):365-372.
24. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103(February 20 (7)):926-933.
25. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121(October (10 Suppl. 1)):S21-S31.
26. Cockerill G.W., Huehns T.Y., Weerasinghe A., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001, 103(January 2 (1)):108-112.
27. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352(January 6 (1)):20-28.
28. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286(July 4 (1)):64-70.
29. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens 2003, 21(October (10)):1787-1803.
30. Arnaud C., Burger F., Steffens S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005, 25(June (6)):1231-1236.
31. Kuijk L.M., Beekman J.M., Koster J., Waterham H.R., Frenkel J., Coffer P.J. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008, 112(November 1 (9)):3563-3573.
32. Caorsi C., Pineda F., Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur Cytokine Netw 2008, 19(June (2)):99-103.
33. Tolonen H, Koponen P, Aromaa A, et al. Review of health examination surveys in Europe. Helsinki, Finland, National Public Health Institute (KTL); 2008. Report No.: B18/2008.